Payment overview · 2025
General Payments
$1,120.50
67 reported records · 20 companies
Healthcare provider profile · identity verified
Jeffry T Evans, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HANNIBAL, MO · NPI 1548249238
Verified facts
What the public records show
CMS Open Payments records show Jeffry T Evans, M.D. received $1,120.50 in general payments during 2025 across 67 reported records.
Novo Nordisk Inc accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $207.30 | 18.5% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $179.31 | 16.0% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $175.79 | 15.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.50 | 15.2% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.48 | 6.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.34 | 3.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $33.53 | 3.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.05 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.13 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.26 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.52 | 2.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.32 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.70 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.31 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.00 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.65 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.98 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.90 | 1.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.59 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.84 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,120.50 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.41 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $144.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $134.42 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.33 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.74 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.74 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.97 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.39 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.77 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.89 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.05 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 60 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 233 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
60 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 866 | 225 |
| Omeprazole | Omeprazole | 681 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 506 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 492 | 119 |
| Lisinopril | Lisinopril | 471 | 121 |
| Metformin Hcl | Metformin Hcl | 463 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 439 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 394 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 98 |
| Losartan Potassium | Losartan Potassium | 347 | 96 |
| Gabapentin | Gabapentin | 311 | 86 |
| Furosemide | Furosemide | 308 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 73 |
| Eliquis | Apixaban | 233 | 43 |
| Carvedilol | Carvedilol | 225 | 57 |
| Pioglitazone Hcl | Pioglitazone Hcl | 219 | 53 |
| Alprazolam | Alprazolam | 205 | 38 |
| Montelukast Sodium | Montelukast Sodium | 202 | 53 |
| Prednisone | Prednisone | 195 | 128 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 72 |
| Tramadol Hcl | Tramadol Hcl | 185 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 180 | 44 |
| Lovastatin | Lovastatin | 177 | 43 |
| Potassium Chloride | Potassium Chloride | 176 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 51 |
| Finasteride | Finasteride | 175 | 43 |
| Ozempic | Semaglutide | 175 | 29 |
| Metformin Hcl Er | Metformin Hcl | 174 | 59 |
| Celecoxib | Celecoxib | 155 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 155 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 49 |
| Azithromycin | Azithromycin | 143 | 109 |
| Clonazepam | Clonazepam | 134 | 23 |
| Pregabalin | Pregabalin | 134 | 24 |
| Meloxicam | Meloxicam | 131 | 42 |
| Glimepiride | Glimepiride | 130 | 37 |
| Allopurinol | Allopurinol | 129 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 37 |
| Lorazepam | Lorazepam | 117 | 22 |
| Simvastatin | Simvastatin | 104 | 26 |
| Famotidine | Famotidine | 103 | 25 |
| Valsartan | Valsartan | 103 | 32 |
| Alendronate Sodium | Alendronate Sodium | 101 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 101 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 93 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 40 |
| Trazodone Hcl | Trazodone Hcl | 88 | 20 |
| Donepezil Hcl | Donepezil Hcl | 87 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 22 |
| Baclofen | Baclofen | 76 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 26 |
| Spironolactone | Spironolactone | 72 | 17 |
| Memantine Hcl | Memantine Hcl | 71 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 21 |
| Sertraline Hcl | Sertraline Hcl | 61 | 22 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 60 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 18 |
| Mounjaro | Tirzepatide | 57 | 13 |
| Valacyclovir | Valacyclovir Hcl | 57 | 25 |
| Warfarin Sodium | Warfarin Sodium | 57 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 14 |
| Ezetimibe | Ezetimibe | 55 | 19 |
| Atenolol | Atenolol | 54 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | 11 |
| Aripiprazole | Aripiprazole | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 17 |
| Jardiance | Empagliflozin | 48 | 13 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 39 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 41 |
| Irbesartan | Irbesartan | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 16 |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 37 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Topiramate | Topiramate | 31 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 15 |
| Naltrexone Hcl | Naltrexone Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,120.50 · 67 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, JOURNAVX, LEQVIO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Veozah, WATCHMAN Access System, Wegovy, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error